BioWorld

April 22, 2008

View Archived Issues

Survival Data Could Threaten Avastin in Lung Cancer Market

Analysts are predicting that Genentech Inc.'s Avastin could face stiff competition as a treatment for lung cancer from ImClone Systems Inc.'s Erbitux (Cetuximab) based on new data. (BioWorld Today) Read More

Series B Round Gains $25M for Stromedix Fibrosis Trial

Read More

Inflammation Increases Fusion of Brain with Blood Stem Cells

Read More

Vernalis Takes $29M for Now, Giving Up Migraine Revenues

Read More

Other News To Note

Read More

Clinic Roundup

Read More

ECCMID Roundup

Read More